patent

Amritsar: Hindu College Professor Patents AI Fielding Device to Revolutionize Cricket Training

by

In a landmark development combining sports and technology, a professor from Hindu College, Amritsar, has been awarded a patent for an innovative AI-powered fielding device aimed at enhancing the training regimens of professional and amateur cricketers alike.

Dr. Rajeev Sharma, Associate Professor of Computer Science at Hindu College, has successfully developed and patented an artificial intelligence-based fielding simulation device that promises to transform how cricketers practice catching, throwing, and reflex-based drills. The device, named “SmartCatch AI”, integrates machine learning algorithms and motion sensors to simulate real-time game scenarios, offering players a dynamic and responsive training environment.

A Fusion of Technology and Cricket

Speaking to reporters, Dr. Sharma expressed his motivation behind the invention: “Fielding is often considered a neglected area during cricket training. Most of the focus traditionally goes to batting and bowling. I wanted to create a solution that uses AI to simulate unpredictable, real-match fielding conditions, helping players build muscle memory and improve agility.”

The SmartCatch AI system consists of a smart ball-launching unit, multiple high-speed sensors, and a mobile app interface. The device uses AI to analyze a player’s reaction time, movement efficiency, and catching technique. It can project balls at varying speeds, angles, and spin, simulating catches and ground fielding challenges from different positions such as slips, covers, and boundaries.

Patent Recognition and Future Plans

The Indian Patent Office officially granted the patent to Dr. Sharma earlier this month after a rigorous evaluation process. The innovation is being hailed as a significant step forward for sports-tech integration in India.

Principal of Hindu College, Dr. Manjit Kaur, lauded the achievement, stating, “This is a proud moment for our institution. Dr. Sharma’s work not only reflects academic excellence but also demonstrates how research can directly contribute to real-world applications in sports.”

Dr. Sharma is currently in talks with the Punjab Cricket Association and several private academies to pilot the device in training programs. There is also growing interest from tech investors and sports equipment manufacturers for possible commercial partnerships.

Supporting Grassroots Cricket

What sets the SmartCatch AI apart is its adaptability for all levels of cricket. While elite cricketers can benefit from advanced analytics, the device is designed to be affordable and user-friendly for use in schools and rural academies as well.

“I envision this tool being used in every cricket academy across India. Whether you’re preparing for the Ranji Trophy or just starting out, this device can elevate your fielding game,” added Dr. Sharma.

A Leap for AI in Sports

This innovation marks a growing trend in India where artificial intelligence is finding its way into traditional domains like sports. With wearable fitness trackers already popular among athletes, the SmartCatch AI could signal a new wave of specialized AI tools designed for sport-specific training.

Dr. Sharma plans to present his research at the upcoming International Conference on Sports Science and Technology later this year and is also working on a collaborative paper with sports physiologists to further refine the device’s impact on athletic performance.

As cricket continues to evolve with technology, the contribution from a college in Amritsar is a reminder that groundbreaking innovation can come from anywhere—when passion meets purpose.

CSIR-IIP Celebrates Rashtriya Boudhik Sampada Mahotsav 2025 to Promote IP Awareness

by

The CSIR-Indian Institute of Petroleum (CSIR-IIP), Dehradun, today celebrated the Rashtriya Boudhik Sampada Mahotsav (RBSM) 2025, a nationwide initiative aimed at fostering awareness about intellectual property (IP) rights and their role in nation-building. The event took place at the institute’s campus with enthusiastic participation from scientists, academicians, students, and industry representatives.

First launched in July 2023 by the Council of Scientific and Industrial Research (CSIR), RBSM seeks to enhance public understanding of intellectual property and to encourage innovation through structured outreach, education, and support.

A Platform to Empower Innovators

The 2025 edition of RBSM at CSIR-IIP was marked by a series of informative sessions, panel discussions, and exhibitions highlighting the role of IP in scientific research, technology development, and economic progress. Experts from the Indian Patent Office, legal practitioners, and innovation strategists spoke on topics ranging from patent filing procedures and IP commercialization to the importance of IP in academic and industrial R&D.

“Protecting and leveraging our intellectual assets is key to strengthening our position in global innovation rankings. RBSM is a unique opportunity to bring IP literacy to the grassroots and ignite the minds of our young innovators,”.

Fostering a Culture of Innovation

The event also featured success stories from CSIR-IIP’s own research and development initiatives, many of which have been protected through patents and licensed to industry partners. A dedicated exhibition showcased the institute’s patent portfolio, technology transfers, and collaborations with startups and MSMEs.

Participants had the opportunity to interact directly with IP professionals through on-site clinics, which offered guidance on patent searches, prior art analysis, and the process of filing for IP protection in India and abroad.

Youth Engagement and Outreach

Special emphasis was placed on engaging students and young researchers. The institute hosted a quiz competition, a poster exhibition, and an essay contest centered on the theme “IP for a Sustainable Future.” These activities were designed to inspire the next generation to think creatively and understand the importance of safeguarding their innovations.

Dr. Renu Singh, Head of CSIR-IIP’s IP Management Cell, highlighted the institute’s efforts to integrate IP education into scientific training. “We are committed to creating an ecosystem where researchers not only innovate but also understand the value of securing their inventions. Through RBSM, we aim to mainstream IP literacy across all levels of education and research,” she stated.

A National Movement for IP Literacy

RBSM is being celebrated simultaneously at various CSIR laboratories and academic institutions across the country. Its overarching goal is to bridge the knowledge gap in IP awareness and promote a culture of innovation, in line with the Government of India’s vision of an Atmanirbhar Bharat (self-reliant India).

As the celebrations concluded, participants reaffirmed their commitment to promoting intellectual property as a critical tool for sustainable development and economic empowerment. The event served as a powerful reminder that India’s intellectual wealth is among its most valuable resources — one that must be nurtured, protected, and celebrated.

For media inquiries, please contact:

Public Relations Office
CSIR-Indian Institute of Petroleum
Dehradun, Uttarakhand
www.iip.res.in

This article is an original report and has not been copied or reproduced from any external sources.

Delhi High Court Restrains Dr. Reddy’s, OneSource in Novo Nordisk’s Weight Loss Drug Patent Dispute

by

In a significant legal development, the Delhi High Court has issued an interim injunction restraining Indian pharmaceutical major Dr. Reddy’s Laboratories and OneSource Nutra from manufacturing, selling, or distributing generic versions of a weight loss drug patented by Danish pharmaceutical company Novo Nordisk.

The dispute centers around semaglutide, the active ingredient in Novo Nordisk’s blockbuster drug Wegovy, which is used for chronic weight management and has gained global popularity due to its high efficacy in combating obesity. Semaglutide, also used in the diabetes medication Ozempic, has seen skyrocketing demand, making it a highly valuable asset for the company.

The Court’s Interim Order

On Thursday, Justice Sanjeev Narula of the Delhi High Court granted an ex parte ad interim injunction in favor of Novo Nordisk, barring Dr. Reddy’s and OneSource from infringing on the company’s patent rights related to semaglutide. The order came in response to a lawsuit filed by Novo Nordisk India Pvt. Ltd. and Novo Nordisk A/S, which alleged unauthorized use and commercialization of the patented compound by the defendants.

The court observed that a prima facie case of patent infringement had been established and that irreparable harm could be caused to Novo Nordisk if interim relief was not granted. The order restrains the defendants from importing, manufacturing, marketing, or offering for sale any product containing semaglutide until the matter is fully adjudicated.

Background of the Dispute

Novo Nordisk holds a valid Indian patent for semaglutide, which is protected until 2033. The company claimed that Dr. Reddy’s and OneSource had begun producing and marketing unauthorized generic versions of the compound in violation of its intellectual property rights.

In its petition, Novo Nordisk argued that such actions not only amounted to infringement but also posed a serious threat to its commercial interests and research investments in India and globally.

The Danish drugmaker submitted evidence including product listings and promotional material from the defendants, suggesting active commercialization efforts despite the subsistence of the patent.

Industry Impact

The injunction is likely to have far-reaching implications for the Indian pharmaceutical sector, particularly in the context of patent law enforcement and the growing market for obesity treatment drugs. With semaglutide-based therapies becoming a major growth driver for Novo Nordisk, the ruling underscores the increasing significance of patent protection in high-value therapeutic categories.

While Indian generic manufacturers have historically played a critical role in making affordable medications accessible, this case reaffirms the judiciary’s stance on respecting patent laws, particularly when infringement is clearly established.

Responses from the Parties

As of the time of publication, Dr. Reddy’s Laboratories has not issued an official statement on the court’s order. OneSource Nutra also remains silent on the issue.

Novo Nordisk, on the other hand, welcomed the decision, stating it was a “vindication of our ongoing commitment to protecting innovation and ensuring patient safety.” The company emphasized that unregulated generics could compromise treatment efficacy and patient outcomes.

Next Steps

The matter is scheduled for further hearing in July 2025, during which the defendants are expected to present their responses. Legal experts suggest that the final outcome could set a precedent for similar cases involving high-demand biologics and patented pharmaceuticals.

As India continues to balance public health interests with intellectual property rights, the resolution of this case will be closely monitored by stakeholders in the pharmaceutical and healthcare sectors both domestically and internationally.

SJTA to Apply for Patents on Key Jagannath Temple Terms and Symbols

by

In a landmark decision aimed at safeguarding the cultural and spiritual heritage of Odisha, the Sri Jagannath Temple Administration (SJTA) has announced plans to seek IP rights for several terms and symbols intrinsically linked to the Jagannath Temple in Puri. The decision was made during a high-level meeting of the temple management committee held in Puri on Monday.

SJTA Chief Administrator Dr. Arabinda Padhee confirmed the move, stating, “It has been approved in a high-level meeting today. The Sri Jagannath Temple Administration will be applying for patents and trademarks on terms like ‘Srimandir’, ‘Jagannath Dham’, ‘Mahaprasad’, the logo of Srimandir, ‘Shrikshetra’, and ‘Purushottam Dham’.”

The decision comes in light of growing concerns over the unauthorized commercial use and potential misrepresentation of sacred and culturally significant names and symbols associated with the Jagannath Temple. By securing legal protection, the SJTA aims to preserve the sanctity of these terms and prevent their exploitation for profit or misuse by private entities.

According to temple officials, the patent applications will be filed under appropriate categories, including trademarks and copyrights, as per the Indian intellectual property laws. The administration will also consult with legal experts and the state’s intellectual property office to ensure a comprehensive and enforceable registration process.

“The Jagannath Temple is not just a religious monument; it is a symbol of Odisha’s spiritual identity and cultural pride,” Dr. Padhee emphasized. “Protecting its symbols and sacred terms is crucial in an era where religious and cultural icons are increasingly commodified.”

The terms selected for protection are deeply rooted in the Jagannath tradition. ‘Srimandir’ refers to the main temple itself, ‘Jagannath Dham’ and ‘Purushottam Dham’ are spiritual designations for the sacred pilgrimage site, and ‘Mahaprasad’ denotes the holy food offering distributed to devotees. The logo of Srimandir and ‘Shrikshetra’, another traditional name for the sacred region, are also widely recognized and respected among devotees and scholars alike.

Once granted, the patents and trademarks will allow SJTA to monitor and regulate the use of these terms, especially in commercial, promotional, or branding contexts. The administration is also expected to develop guidelines for permissible use by religious organizations and devotees, ensuring a balance between protection and public reverence.

The move has been largely welcomed by cultural experts and religious scholars, who view it as a proactive step toward preserving the unique spiritual heritage of the Jagannath tradition.

The Sri Jagannath Temple in Puri, a major center of Hindu pilgrimage and a site of immense historical and religious significance, attracts millions of devotees from across India and abroad every year. The temple’s traditions, including the annual Rath Yatra, have a deep cultural impact that extends far beyond Odisha.

With the temple administration taking these protective measures, it marks a significant moment in the intersection of law, religion, and cultural preservation in India.

SINTX Technologies Sparks Investor Interest with New Patent and Strategic Subsidiary Move

by

SINTX Technologies, Inc. (NASDAQ: SINT), a leader in advanced ceramics, has recently drawn significant attention from retail investors following the issuance of a pivotal U.S. patent and the strategic divestiture of a subsidiary.

Strengthening the Patent Portfolio

SINTX announced the issuance of U.S. Patent No. 12,239,761, a development that bolsters its intellectual property portfolio.  This patent covers innovative methods for adhering silicon nitride to various biomaterial substrates, enhancing biocompatibility and resistance to infection.  The technology has potential applications across orthopedic, dental, and spinal implants, aligning with SINTX’s mission to improve patient outcomes and surgical success rates. 

Eric K. Olson, President and CEO of SINTX, emphasized the significance of this advancement: “With its antiviral, antibacterial, and biomechanical advantages, silicon nitride continues to demonstrate its potential in medical implants, regenerative medicine, and advanced coating technologies.” 

Strategic Divestiture to Focus on Core Competencies

Market Response and Financial Outlook

Following these announcements, SINTX’s stock experienced increased trading activity.  As of the latest trading session, the stock is priced at $2.69, reflecting a slight decrease of 0.71% from the previous close.  The day’s trading range saw a high of $2.84 and a low of $2.50, with a volume of 158,621 shares. 

The company’s recent actions have positioned it favorably in the competitive landscape of advanced ceramics and biomedical applications.  With a robust patent portfolio and a clear focus on core competencies, SINTX is poised for continued innovation and growth in the medical device sector.

Newgen Software Granted Indian Patent for Groundbreaking Data Compression Innovation

by

Newgen Software Technologies Ltd., a global leader in digital transformation solutions, has secured a significant milestone with the grant of a new patent by the Indian Patent Office. The patent, titled “System and Method for Data Compression” (Patent No. 565385), has been awarded for a 20-year term beginning April 26, 2017, under the provisions of the Indian Patents Act, 1970.

This latest patent highlights Newgen’s commitment to continuous innovation in the field of enterprise software and data management. The patented system introduces a novel approach to data compression, specifically designed to efficiently manage large volumes of files that contain mostly repetitive content with only small portions of variable data. Such data patterns are common in sectors like finance, healthcare, and government operations where document generation is highly templated.

Addressing Limitations of Traditional Techniques

Traditional data compression algorithms often struggle with files that, while large, differ only slightly from one another. These conventional methods may fail to deliver meaningful storage reductions or may compromise processing speed in such use cases. Newgen’s patented solution seeks to overcome these challenges by employing a more intelligent and adaptive method that focuses on identifying and compressing recurring content while effectively managing the dynamic parts of the data.

According to Newgen, the invention not only enhances compression ratios but also boosts the overall performance of data handling systems. By significantly reducing storage requirements and improving the efficiency of data transmission and retrieval, the technology has the potential to deliver substantial cost and resource savings for organizations managing extensive digital archives.

A Step Forward in Enterprise Efficiency

Speaking on the development, a Newgen spokesperson stated, “This patent is a testament to our continuous efforts to push the boundaries of enterprise innovation. Efficient data compression is critical in today’s digital landscape where businesses deal with massive volumes of structured and unstructured information. Our solution provides a smarter alternative to conventional techniques and can be a game-changer for industries dealing with high-volume, low-variance data.”

Newgen Software has a strong track record of investing in research and development, with a growing portfolio of patents that span process automation, document management, and AI-driven analytics. The newly patented data compression system is expected to be integrated into its existing platforms and may also be offered as a standalone solution for enterprises looking to optimize their data infrastructure.

About Newgen Software

Headquartered in New Delhi, Newgen Software is a global provider of low-code digital automation platforms that drive smarter processes and simpler customer journeys. The company’s solutions are widely used across banking, insurance, healthcare, government, and other sectors to automate complex business processes and enhance digital experiences.

Chandigarh Students Secure Patent for ‘GestureX’ – Revolutionary Smart Glasses that Translate Speech into Sign Language

by

In a breakthrough moment for accessible technology in India, a team of students from Chandigarh has been awarded a design patent for their innovative invention – GestureX, a pair of smart glasses that can convert spoken language into sign language in real-time. This pioneering project aims to bridge communication gaps for the hearing-impaired, enhancing inclusivity in education, workplaces, and daily life.

Breaking Communication Barriers with Technology
GestureX represents a significant leap in assistive wearable technology. The device is expected to transform how individuals with hearing disabilities interact with the world around them, particularly in environments where sign language interpreters are unavailable.

The patent, granted under Class 16-06 (relating to communication equipment), marks formal recognition of the students’ innovation, positioning GestureX as a potential game-changer in inclusive communication tools.

How GestureX Works
The functionality of GestureX is underpinned by a combination of hardware and software components that work seamlessly together:

Built-in Microphones: The glasses are fitted with directional microphones that capture ambient speech in real-time.

Speech Recognition Engine: Advanced software processes spoken words and converts them into text-based commands.

Sign Language Renderer: A miniature display system integrated into the glasses projects animated sign language gestures that correspond to the recognized speech.

Efficient Power Management: Designed with lightweight battery systems, GestureX ensures portability and extended battery life for regular use.

The glasses have been optimized to recognize multiple accents and background noise, ensuring accuracy in varied environments like classrooms, conferences, or public transport.

Designed by Students, Backed by Innovation
The team behind GestureX comprises students from diverse technical backgrounds who came together with a shared vision to make technology more inclusive. Motivated by personal experiences and community challenges, the team sought to develop a tool that could empower the deaf and hard-of-hearing communities with greater independence and confidence.

According to the team spokesperson, “Our goal was to build something meaningful that could help real people in real situations. GestureX is not just a gadget—it’s a step toward equal access and inclusive communication.”

Broader Implications and Future Development
GestureX’s creators are in discussions with academic institutions and healthcare providers to initiate pilot testing of the device. Early trials will help refine the technology, particularly for use in multilingual settings where regional sign language variants are common.

Looking ahead, the team plans to integrate artificial intelligence to allow the glasses to adapt to individual speech patterns, improve gesture accuracy, and potentially support reverse translation—from sign language to spoken words—to facilitate two-way communication.

They are also exploring partnerships for manufacturing and scaling the product, with the aim of keeping it affordable for individuals and organizations that serve the deaf and hard-of-hearing communities.

A Leap Forward in Assistive Tech
As India continues to promote inclusive innovation through programs like Startup India and the Atal Innovation Mission, projects like GestureX highlight the role of youth-led innovation in solving socially relevant problems. The device stands as a testament to the power of interdisciplinary collaboration and the potential for accessible design to foster greater equity in communication.

If successfully commercialized, GestureX could join the ranks of transformative assistive devices, not only within India but globally, providing a much-needed communication bridge in an increasingly interconnected world.

University of Hyderabad Researchers Secure Patents for Pioneering Innovations in Materials Science

by
The University of Hyderabad (UoH), one of India’s premier research institutions, continues to solidify its reputation in scientific innovation, with two newly granted patents in the field of materials science and microwave technology.

The patents, awarded to faculty members from the School of Physics and the Advanced Centre of Research in High Energy Materials (ACRHEM), underscore UoH’s growing impact in high-performance materials research with wide-ranging industrial applications.

Innovation in 3D Ceramic Resonators
The first patent, titled “Dielectric Resonators with Complex 3D Geometries Using Gel Casting Techniques,” is credited to Professors K.C. James Raju and V. Seshubai, along with research scholars T. Anil and Swarup Raju. This novel method facilitates the production of high-temperature ceramic dielectric resonators molded into intricate three-dimensional structures.

Traditionally, creating 3D resonators from ceramic materials poses significant challenges due to their brittle nature and high processing temperatures. The patented gel casting approach overcomes these limitations, enabling the fabrication of compact and high-performance resonators suitable for next-generation microwave and millimeter-wave communication systems.

“This technique opens new pathways for designing miniaturized antennas and frequency filters, particularly in 5G and satellite communication devices,” explained Prof. Raju.

Breakthrough in Low-Temperature Crystallization
The second patent focuses on the laser-based crystallization of ferroelectric thin films, a breakthrough that significantly lowers the thermal requirements for these critical materials. Spearheaded again by Prof. K.C. James Raju and his team, the technique successfully reduces the crystallization temperature from 700°C to 300°C by utilizing controlled laser irradiation.

This innovation has significant implications for the electronics industry, particularly in the integration of ferroelectric materials into semiconductor devices, which typically cannot endure high processing temperatures. Lower thermal thresholds enable the application of these films in tunable microwave components, sensors, and energy-efficient electronic devices.

“This development bridges the gap between high-performance ferroelectric materials and practical device manufacturing,” noted Prof. Raju.

UoH’s Growing Patent Portfolio
With these two patents, the University of Hyderabad continues to expand its footprint in applied scientific research and industrial collaboration. The institution has increasingly focused on promoting innovation that addresses real-world challenges in communication, electronics, and advanced materials.

Vice-Chancellor Prof. B.J. Rao praised the research teams for their work, stating, “These achievements are a testament to the University’s commitment to fostering a research environment that supports both theoretical advancement and practical application.”

Looking Ahead
As global industries seek cost-effective and scalable technologies in electronics and telecommunications, the breakthroughs from UoH researchers could play a pivotal role in shaping future solutions. The university also aims to collaborate with industries and startups to bring these patented technologies from the lab to the market.

While the university has yet to announce any patent specifically related to alpha alumina platelets, these recent innovations indicate that UoH remains a leader in cutting-edge materials science research with broad commercial potential.

Donald Trump Urged to Target ‘Lazy Patent Expansion’ in U.S. Drug Bill Push

by
In a significant development in the ongoing debate over U.S. drug pricing, Richard Saynor, CEO of Sandoz, a leading generic pharmaceutical company, has called on former President Donald Trump to address the issue of “lazy patent expansion” in his efforts to reduce prescription drug costs. Saynor’s remarks come as Trump seeks to implement a “most favored nation” policy, aiming to align U.S. drug prices of other nations. While supporting this initiative, Saynor emphasized the need for reform in the generics market to ensure sustainable access to affordable medications.

The Problem: Patent Thickets and Evergreening
Saynor criticized the practice of “evergreening,” where brand-name drug manufacturers file numerous patents on slight modifications of existing drugs to extend their market exclusivity. This strategy, often referred to as creating “patent thickets,” has been used to delay the entry of generic competitors, thereby maintaining high drug prices. For instance, blockbuster drugs like AbbVie’s Humira have been subject to extensive patent filings, with over 140 patents filed per top-selling drug, causing prices to remain high and limiting competition.

Impact on Generic Drug Market
Generic drugs account for approximately 90% of prescriptions in the U.S. and are significantly more affordable than their branded counterparts. However, the proliferation of patent thickets has led to shortages and limited availability of generics. Saynor highlighted that the rebate system, which involves pharmacy benefit managers, further inflates drug costs, making it more challenging for generics to compete.

Proposed Solutions
To address these issues, Saynor advocated for reinstating a six-month exclusivity period for first-to-market generics, a policy that could incentivize the development and availability of affordable alternatives. Additionally, he cautioned against proposed pharmaceutical tariffs, which could disproportionately impact generics due to their low margins and reliance on overseas production.

Legislative Efforts and Challenges
Bipartisan efforts to reform the patent system have been introduced in Congress, targeting practices like patent thickets, product hopping, and pay-for-delay agreements. Despite strong support, these bills have faced obstacles in becoming law, often due to legislative gridlock and opposition from industry stakeholders.

Global Implications
Trump’s “most favored nation” policy, which seeks to align U.S. drug prices with those paid by other countries, has raised concerns internationally. In the UK, for example, where branded drugs cost significantly less than in the U.S., pharmaceutical firms may respond by raising prices elsewhere or withholding drugs from certain markets. This could strain healthcare systems globally and potentially discourage pharmaceutical innovation.

Conclusion
As the U.S. continues to grapple with high drug prices, addressing the issue of “lazy patent expansion” is crucial for fostering a competitive and affordable pharmaceutical market. While Trump’s policy initiatives aim to reduce costs, comprehensive reform of the patent system is necessary to ensure long-term access to essential medications for all Americans.

Biofrontera Inc. Secures Extended Patent Protection for Ameluz® and Completes Patient Enrollment in Phase 2b Acne Study

by

Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in dermatological treatments, has announced two significant milestones: the extension of U.S. patent protection for its flagship product, Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, and the completion of patient enrollment in its Phase 2b clinical trial evaluating Ameluz® for the treatment of moderate to severe acne vulgaris.

Extended Patent Protection for Ameluz®

The U.S. Patent and Trademark Office (USPTO) has granted Biofrontera a new patent related to a photodynamic therapy (PDT) protocol that is expected to be less painful while maintaining efficacy. This patent extends the protection of Ameluz®-PDT through October 2040. Further patents are pending, which may extend protection until 2043 or beyond. 

This extension fortifies Biofrontera’s intellectual property portfolio, ensuring prolonged market exclusivity for Ameluz® and its associated PDT protocols. The company anticipates that this will bolster its competitive position in the dermatological therapeutics market.

Completion of Phase 2b Acne Study Enrollment

In parallel, Biofrontera has successfully completed patient enrollment in its Phase 2b clinical trial assessing the efficacy and safety of Ameluz® for treating moderate to severe acne vulgaris.  This randomized, double-blind study aims to explore the potential of Ameluz® as a novel PDT option for acne, a condition affecting millions worldwide.

The trial’s completion of enrollment marks a significant step toward expanding the indications for Ameluz®.  Pending positive outcomes, Biofrontera plans to advance to Phase 3 trials, with the goal of submitting a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026. 

Strategic Outlook

These developments underscore Biofrontera’s commitment to innovation in dermatological therapies.  By securing extended patent protection and advancing clinical research, the company aims to enhance its product offerings and address unmet needs in skin health.

With the extended patent life of Ameluz® and the progression of its acne treatment program, Biofrontera is poised to strengthen its market presence and deliver value to both patients and shareholders in the coming years.